Avantax Advisory Services Inc. Purchases 17,054 Shares of Pfizer Inc. (NYSE:PFE)

Avantax Advisory Services Inc. boosted its position in Pfizer Inc. (NYSE:PFE) by 5.1% in the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 348,990 shares of the biopharmaceutical company’s stock after acquiring an additional 17,054 shares during the quarter. Avantax Advisory Services Inc.’s holdings in Pfizer were worth $9,259,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Retirement Wealth Solutions LLC bought a new stake in Pfizer during the 4th quarter worth approximately $26,000. Rialto Wealth Management LLC bought a new stake in Pfizer during the 4th quarter worth approximately $26,000. Gladius Capital Management LP increased its holdings in Pfizer by 102.8% during the 3rd quarter. Gladius Capital Management LP now owns 1,043 shares of the biopharmaceutical company’s stock worth $30,000 after purchasing an additional 38,015 shares in the last quarter. Kohmann Bosshard Financial Services LLC bought a new stake in Pfizer during the 4th quarter worth approximately $28,000. Finally, Noble Wealth Management PBC bought a new stake in Pfizer during the 4th quarter worth approximately $31,000. 68.36% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of brokerages have commented on PFE. StockNews.com lowered Pfizer from a “strong-buy” rating to a “buy” rating in a report on Wednesday, November 20th. Guggenheim restated a “buy” rating on shares of Pfizer in a research note on Wednesday. Hsbc Global Res upgraded Pfizer to a “strong-buy” rating in a research note on Monday. Citigroup cut their target price on Pfizer from $30.00 to $29.00 and set a “neutral” rating on the stock in a research note on Tuesday, January 28th. Finally, Wolfe Research began coverage on Pfizer in a research note on Friday, November 15th. They issued an “underperform” rating and a $25.00 target price on the stock. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating, six have issued a buy rating and three have assigned a strong buy rating to the company. Based on data from MarketBeat, Pfizer currently has a consensus rating of “Moderate Buy” and a consensus price target of $31.92.

Insiders Place Their Bets

In related news, Director Ronald E. Blaylock bought 19,457 shares of the company’s stock in a transaction on Thursday, February 13th. The shares were purchased at an average price of $25.65 per share, for a total transaction of $499,072.05. Following the completion of the transaction, the director now directly owns 27,707 shares in the company, valued at approximately $710,684.55. The trade was a 235.84 % increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Company insiders own 0.06% of the company’s stock.

Pfizer Price Performance

Pfizer stock opened at $25.60 on Friday. Pfizer Inc. has a 12 month low of $24.48 and a 12 month high of $31.54. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63. The business’s 50 day simple moving average is $26.26 and its 200 day simple moving average is $27.17. The company has a market cap of $145.08 billion, a price-to-earnings ratio of 18.16, a PEG ratio of 0.64 and a beta of 0.61.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.48 by $0.15. The firm had revenue of $17.76 billion for the quarter, compared to the consensus estimate of $17.26 billion. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The business’s quarterly revenue was up 24.7% on a year-over-year basis. During the same quarter in the prior year, the business posted $0.10 earnings per share. Sell-side analysts forecast that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.